The Pfizer competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides details regarding specific areas of interest, sets timelines for review and approval. AGA will select the Expert Review Panel (ERP) to make final grant decisions, create a community of practice for the selected Grantees and share existing knowledge and tools.

Areas of Interest

• Specific Area of Interest for this RFP:
  • The Request for Proposals (RFP) from the AGA-Pfizer collaboration seeks submissions that are focused on new research areas that could improve the diagnosis and treatment of inflammatory bowel disease (IBD). Specific areas of interest include:
    • Use of real-world data to model IBD practice patterns
    • Areas specific to S1P receptor modulators.
      • Elucidate the role of S1P receptor modulators in extra-intestinal manifestations of IBD.
      • Evaluation of S1P receptor modulators in IBD as combination or sequenced treatment with immunosuppressants/advanced therapies.
      • Evaluate efficacy and safety of S1P receptor modulators in other gastrointestinal (GI) conditions such as eosinophilic esophagitis, Crohn’s disease, pouchitis, proctitis, pancolitis, microscopic colitis, and checkpoint inhibitor induced colitis.
    • Areas specific to innovative or novel methods of disease diagnosis and/or monitoring.
      • Use of artificial intelligence/machine learning to identify or select patients with IBD who are likely to respond to specific therapeutics.
      • Evaluate the effectiveness of intestinal ultrasound (IUS) in monitoring patient responses to treatment, with a focus on, but not limited to, S1P receptor modulators.
      • Explore the clinical utility of IUS in monitoring disease activity and extent, as well as tracking changes in disease activity in conjunction with treatment.
      • Investigate the role of IUS in guiding IBD care, supporting long-term clinical remission, and preventing complications, while addressing optimal techniques and limitations.
      • Use of artificial intelligence (AI) in endoscopic assessments of the intestinal tract.
      • Implementation of treat to target strategies in disease monitoring.
      • Leverage rich clinical, biomarker and/or -omics data to predict treatment responses in IBD.

Funding Information

• Individual projects requesting up to $60,000 will be considered.
• Maximum project length is 1 year.

Eligibility Criteria

• Geographic Scope:
  • United States
• The PI is a member of the American Gastroenterological Association.
• The institution and Principal Investigator (PI) must be based in one of the eligible countries noted above.
• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society). Pfizer cannot provide grants to individuals, individually owned private physician practices or informal groups which are not legal entities.
• If the project involves multiple departments within an institution and/or between different institutions / associations, all institutions must have a relevant role, and the requesting organization must have a key role in the project.
• The PI must have a medical or doctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
• The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
• The PI must be an employee or contractor of the requesting organization.
• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. They strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
• Pfizer grants support a wide variety of organizations, all of which are legal entities. These include accredited medical schools or academic hospitals; other medical centers focused on patient care and residency training, not necessarily affiliated with universities; medical, scientific, or professional associations, non-profit patient organizations, non-profit civic organizations that advocate for patients, support research, and improve healthcare.

For more information, visit Pfizer.

https://cdn.pfizer.com/pfizercom/2025-07/2025-I%26I-US-AGA-IBD-DiagnosisTreatment-RES.pdf?VersionId=.S7wpXw2KwiX0m8kVQ4dywOD_KnoutDG